Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Enanta Pharmaceuticals (ENTA) Return on Sales (2016 - 2025)

Historic Return on Sales for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q4 2025 value amounting to 0.64%.

  • Enanta Pharmaceuticals' Return on Sales rose 6700.0% to 0.64% in Q4 2025 from the same period last year, while for Dec 2025 it was 1.07%, marking a year-over-year increase of 5100.0%. This contributed to the annual value of 1.25% for FY2025, which is 4600.0% up from last year.
  • As of Q4 2025, Enanta Pharmaceuticals' Return on Sales stood at 0.64%, which was up 6700.0% from 1.23% recorded in Q3 2025.
  • Enanta Pharmaceuticals' Return on Sales' 5-year high stood at 0.64% during Q4 2025, with a 5-year trough of 2.12% in Q1 2023.
  • For the 5-year period, Enanta Pharmaceuticals' Return on Sales averaged around 1.46%, with its median value being 1.4% (2023).
  • Its Return on Sales has fluctuated over the past 5 years, first tumbled by -15800bps in 2021, then skyrocketed by 8100bps in 2024.
  • Over the past 5 years, Enanta Pharmaceuticals' Return on Sales (Quarter) stood at 1.09% in 2021, then decreased by -13bps to 1.23% in 2022, then crashed by -51bps to 1.86% in 2023, then grew by 29bps to 1.31% in 2024, then soared by 51bps to 0.64% in 2025.
  • Its last three reported values are 0.64% in Q4 2025, 1.23% for Q3 2025, and 1.0% during Q2 2025.